In vivo inferiority of generic product compared with branded vancomycin: a paradigm shift.

摘要

Each year, Americans save an estimated Dollars 8 billion to Dollars 10 billion at retail pharmacies by purchasing generic drags rather than brand-name medications, the US Food and Drag Administration reports.1 The US Food and Drag Administration and other drag regulatory agencies, such as the European Medicines Agency, support commercialization of generic drugs because it controls costs and because genetics are an essential therapeutic option in developing countries.1'2 Lower cost is the key advantage of generics because they mostly do not need further development, are relatively easily approved, and have often already won a share of the consumer market.